BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 20601799)

  • 1. Updates of adjuvant therapy in pancreatic cancer: where are we and where are we going? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010.
    Li J; Merl MY; Chabot J; Saif MW
    JOP; 2010 Jul; 11(4):310-2. PubMed ID: 20601799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Second line therapy for advanced pancreatic adenocarcinoma: where are we and where are we going? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010.
    Brus C; Saif MW
    JOP; 2010 Jul; 11(4):321-3. PubMed ID: 20601802
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant Therapy of Pancreatic Cancer. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011.
    Sharma C; Horowitz D; Chabot J; Saif MW
    JOP; 2011 Jul; 12(4):343-6. PubMed ID: 21737892
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjuvant treatment for ampullary cancer. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011.
    Kim R; Chabot J; Saif MW
    JOP; 2011 Jul; 12(4):362-3. PubMed ID: 21737897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Updates in locally advanced pancreatic cancer. Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010.
    Chang BW; Siccion E; Saif MW
    JOP; 2010 Jul; 11(4):313-6. PubMed ID: 20601800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Updates in pancreatic neuroendocrine carcinoma. Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010.
    Alsamarai S; Libutti SK; Saif MW
    JOP; 2010 Jul; 11(4):336-40. PubMed ID: 20601807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Locally advanced pancreatic adenocarcinoma: are we making progress?. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011.
    Li J; Ng J; Allendorf J; Saif MW
    JOP; 2011 Jul; 12(4):347-50. PubMed ID: 21737893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-line treatment of metastatic pancreatic adenocarcinoma: can we do better? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010.
    Merl MY; Abdelghany O; Li J; Saif MW
    JOP; 2010 Jul; 11(4):317-20. PubMed ID: 20601801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Updates on first-line treatment of metastatic pancreatic adenocarcinoma. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011.
    Strimpakos AS; Syrigos KN; Saif MW
    JOP; 2011 Jul; 12(4):339-42. PubMed ID: 21737891
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetics and other molecular targets in the management of pancreatic adenocarcinoma. Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010.
    Merika E; Syrigos KN; Saif MW
    JOP; 2010 Jul; 11(4):328-30. PubMed ID: 20601804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diabetes and pancreatic cancer. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011.
    Hsu C; Saif MW
    JOP; 2011 Jul; 12(4):330-3. PubMed ID: 21737889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcome of pancreatic cancer patients with diabetes mellitus: is diabetes a poor prognostic factor? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010.
    Kang SP; Saif MW
    JOP; 2010 Jul; 11(4):334-5. PubMed ID: 20601806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Palliative care of pancreatic cancer. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011.
    Saif MW
    JOP; 2011 Jul; 12(4):355-7. PubMed ID: 21737895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel agents in the treatment of unresectable neuroendocrine tumors. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011.
    Oberstein PE; Saif MW
    JOP; 2011 Jul; 12(4):358-61. PubMed ID: 21737896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel agents for the treatment of pancreatic adenocarcinoma: any light at the end of the tunnel? Highlights from the "2010 ASCO Annual Meeting". Chicago, IL, USA. June 4-8, 2010.
    Dimou AT; Syrigos KN; Saif MW
    JOP; 2010 Jul; 11(4):324-7. PubMed ID: 20601803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel agents for the treatment of pancreatic adenocarcinoma. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011.
    Cheng H; Merika E; Syrigos KN; Saif MW
    JOP; 2011 Jul; 12(4):334-8. PubMed ID: 21737890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biomarkers and pharmacogenetics in pancreatic cancer. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011.
    Xu X; Strimpakos AS; Saif MW
    JOP; 2011 Jul; 12(4):325-9. PubMed ID: 21737888
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Locally advanced pancreatic adenocarcinoma: where are we and where are we going? Highlights from the "2010 ASCO Gastrointestinal Cancers Symposium". Orlando, FL, USA. January 22-24, 2010.
    Richter J; Saif MW
    JOP; 2010 Mar; 11(2):139-43. PubMed ID: 20208322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant treatments for resectable pancreatic cancer.
    Ueno H; Kosuge T
    J Hepatobiliary Pancreat Surg; 2008; 15(5):468-72. PubMed ID: 18836798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant therapy of pancreatic cancer.
    Hilbig A; Oettle H
    Expert Rev Anticancer Ther; 2010 Apr; 10(4):485-91. PubMed ID: 20397913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.